ACAD · Healthcare
Acadia Pharmaceuticals Inc
28/100
Smart-money confidence1 of 3 sources positive
Weak — few signals
No standout activity across the feeds we track.
Hedge funds
38
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Market cap
$5.0B
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqGS
About ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin,…
Who's behind the signal
Every informed buyer we can see on ACAD, across all three feeds.
Hedge funds · 7
Bridgewater Associates (Dalio)
Increased +3%
Millennium Management (Englander)
Increased +27%
Gotham Asset Mgmt (Greenblatt)
Increased +119%
Point72 (Steve Cohen)
Decreased −24%
D.E. Shaw & Co
Decreased −29%
Citadel Advisors
Decreased −54%
+1 more in the full breakdown below ↓
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Congressional trades · 2 on record
Disclosures from 2020-09-08 to 2022-06-16
The newest disclosure we hold for this stock is 2022-06-16.
That is the end of our data, not necessarily the end of the trading — our
bulk STOCK Act archive stops there and newer filings arrive through a
separate live feed. Treat the absence of recent rows as “not covered”,
not as “no trades”.
| Trade date | Member | Chamber | Action | Amount |
|---|---|---|---|---|
| 2022-06-16 | Chris Jacobs · R-NY | House | Sold | $1,001 - $15,000 |
| 2020-09-08 | Chris Jacobs · R-NY | House | Sold | $1,001 - $15,000 |
Not a model pick — but on our radar.
ACADIA PHARMACEUTICALS INC isn't in the top-10 model right now, but 7 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
7
Investors
0
New positions
3
Increasing
4
Decreasing
0
Unchanged
Price History
Loading price data...
Return:
High:
Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.3×
% of portfolio
0.0%
Position change
+3%
0.0% of Bridgewater Associates's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+27%
0.0% of Millennium Management's portfolio
Trust weight: 1.1×
% of portfolio
0.0%
Position change
+119%
0.0% of Gotham Asset Mgmt's portfolio
Trust weight: 1.1×
% of portfolio
0.1%
Position change
−24%
0.1% of Point72's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−29%
0.0% of D.E. Shaw & Co's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−54%
0.0% of Citadel Advisors's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−13%
0.0% of AQR Capital Management's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to ACADIA PHARMACEUTICALS INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell ACADIA PHARMACEUTICALS INC or any security.
订阅每周更新
我们每周会把巴菲特、达利欧、阿克曼以及另外 47 位传奇投资人正在买入的股票发送给你 — 免费，直接来自他们的 SEC 申报文件。
永久免费 · 无垃圾邮件 · 随时退订